FOXO4-DRI vs Humanin
Emerging vs Moderate Research
compatible Different mechanisms; Humanin protects healthy cells while FOXO4-DRI clears senescent ones.
Molecular Data
FOXO4-DRI Humanin
Weight ~4,800 Da 2,687 Da
Half-life Not established ~30 minutes (mice), >4 hours (rats)
Chain ~45 amino acids 24 amino acids
Type D-retro-inverso peptide Mitochondria-derived peptide
Key Benefits
FOXO4-DRI
01 Selective elimination of senescent cells
02 Restoration of tissue homeostasis
03 Improved fitness and physical function in aged models
04 Restored fur density in aged mice
05 Improved kidney function
06 Alleviates chemotherapy-induced senescence
07 Restores testosterone in aged males
08 Reduces senescent chondrocytes in cartilage
09 High selectivity spares healthy cells
Humanin
01 Potent neuroprotection against Alzheimer's and Parkinson's pathology
02 Extended lifespan in animal models (C. elegans)
03 Improved metabolic healthspan parameters
04 Reduced inflammatory markers
05 Cytoprotective effects across multiple cell types
06 Anti-apoptotic activity
07 Mitochondrial optimization and biogenesis
08 Protection against oxidative stress
Dosing Protocols
FOXO4-DRI
25-33 mg per injection (based on mouse study 5 mg/kg) / 3 doses total, administered every other day (Day 1, 3, 5)
Standard senolytic protocol 25-33 mg 3 doses, every other day (6 days total)
Mouse study equivalent 5 mg/kg (translates to ~25 mg for 60kg human) 3 doses on alternate days
Humanin
1-5 mg per injection (0.5-2 mg for HNG analog) / 2-3 times weekly for sustained mitochondrial support
Neuroprotection 1-5 mg 2-3x weekly
Longevity/Anti-aging 1-3 mg 2x weekly
HNG analog 0.5-2 mg 2x weekly
Side Effects
FOXO4-DRI
Limited human data available
Generally well-tolerated in animal studies
Humanin
Injection site reactions
Mild fatigue initially
Headache (rare)
Contraindications
Not yet approved for human use
Pregnancy or breastfeeding
Unknown safety in immunocompromised individuals
Active cancer (theoretical - consult oncologist)
Active cancer (theoretical concern with anti-apoptotic effects)
Pregnancy or breastfeeding
Hypersensitivity to peptide components
Research Evidence
FOXO4-DRI Humanin
Status Emerging Moderate Research
References 5 studies 4 studies
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.